Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway. - barrons.com

By Mackenzie Tatananni | Published: Aug 04, 2026

Pfizerlifted the bottom end of its full-year revenue guidance on Tuesday, citing growth in its non-Covid pharmaceutical portfolio. Its smaller Covid vaccine partner offered a less optimistic outlook.… [+99 chars]